1 The Effect of Intradialytic Exercise on Calcium, Phosphorus

2 and Parathyroid Hormone: A Randomized Controlled Trial

3

4 Mohammadali Tabibi^{*1}, Kenneth R Wilund², Nasrin Salimian³, Saghar Nikbakht⁴, Mahsa

5 Soleymany⁵, Zahra Roshanaeian⁶, Saghar Ahmadi⁷

- 6
- ⁷ ¹Department of Exercise Physiology, Pardis Specialized Wellness Institute, Isfahan, Iran
- 8 ²Department of Kinesiology and Community Health, Division of Nutritional Sciences,
- 9 University of Illinois at Urbana-Champaign, USA.
- ³ Department of Statistics and Community Development, Pardis Specialized Wellness Institute,
- 11 Isfahan, Iran
- ⁴ Department of Kinsiology, Pardis Specialized Wellness Institute, Isfahan, Iran
- ⁵ Department of Exercise Physiology, Pardis Specialized Wellness Institute, Isfahan, Iran
- ³ Department of Sport Nutrition, Pardis Specialized Wellness Institute, Isfahan, Iran
- ⁷ Department of Health and Palliative Care, Pardis Specialized Wellness Institute, Isfahan, Iran

16

- 17 Short Title: Exercise in HD RCT
- **18 Address for Correspondence:**
- 19 MohammadAli Tabibi
- 20 No32, Arbab St, Isfahan, Iran.
- 21 Phone: +989132051202, +983135229060
- 22 Fax: +983135229060
- 23 Email: m.tabibi@ut.ac.ir

24

25 Abstract

26 Introduction

Patients with kidney failure experience derangements of circulating markers of mineral metabolism and dysregulation of skeletal and cardiovascular physiology which results in high mortality rate in these patients. This study aimed to evaluate the effect of intradialytic concurrent exercise on regulation of theses abnormalities related parameters in patients receiving hemodialysis (HD).

32 Methods

In this randomized controlled trial conducted in a HD center in Iran, adult patients receiving chronic HD were randomized to intradialytic exercise (60 minutes) in the second hour of thrice weekly dialysis for 6 months (intervention) or no intradialytic exercise (control). The primary outcomes were serum calcium, serum phosphorous and parathyroid hormone levels. Secondary outcomes were serum alkaline phosphatase and calcium-phosphorous product

38 **Results**

47	Conclusion
46	
45	calcium-phosphorous product ($P < 0.05$).
44	significant decrease in serum phosphorous, parathyroid hormone, alkaline phosphatase and
43	Statistical analyses reveal a significant increase in serum calcium ($P < 0.05$) as well as a
42	significant decrease in serum levels of phosphorous and parathyroid hormone (P < 0.05).
41	and secondary outcomes between the intervention and control groups. The analysis showed a
40	the 6-month intervention period, significant between-group changes were observed in all primary
39	The study included 44 participants randomized to intervention (n=22) or control (n=22). During

Intradialytic exercise performed for at least 60 minutes during thrice weekly dialysis sessions improves bone mineral metabolism in adult patients receiving HD. Further studies should focus on observing the effect of different types of exercise on bone mineral disorders and all-cause mortality in HD patients.

52

53 **Trial registration**

54 ClinicalTrials.gov Identifier: NCT04916743, Registered on June 8th,2021. Registered trial name:

55 The Effect of Intradialytic Exercise on Calcium, Phosphorous and Parathyroid Hormone: A

56 Randomized Controlled Trial

57 Key words: Mortality, Exercise during dialysis, Bone mineral disorders, Cardiovascular disease,
58 Hematological Parameters

59

60 Introduction

61 In recent years, there has been a rapid increase in the prevalence of patients with end stage 62 kidney disease (ESKD) that require kidney replacement therapy, including hemodialysis (HD), 63 peritoneal dialysis (PD) or kidney transplant [1]. ESKD patients, especially those on HD and PD, 64 experience high rates of functional impairment, morbidity, hospitalization, and mortality [2, 3]. 65 These outcomes are an urgent priority for patients, caregivers and healthcare professionals [4, 5]. The primary etiological factors responsible for these outcomes include cardiovascular disorders, 66 67 muscle atrophy and malnutrition [3]. Cardiovascular disease in ESKD patients is associated with traditional risk factors (diabetes, hypertension, sedentary lifestyle) as well as nontraditional factors 68 (anemia, inflammation, abnormal calcium and phosphorus metabolism and oxidative stress) [6]. 69 High levels of calcium, phosphorus, calcium- phosphorus product and parathyroid hormone are 70 71 associated with all causes of mortality in dialysis patients [7]. Hyperphosphatemia is also a common complication in ESKD. As renal excretion of phosphorus decreases, this results in 72 73 increased serum levels of phosphorus and hyperphosphatemia. Calcium and parathyroid hormone are phosphorus-dependent. Hyperphosphatemia alone or in combination with hypercalcemia is 74 75 associated with increased mortality in hemodialysis patients. Phosphate metabolism is regulated by the interaction of the kidneys, bones, and intestines. This balance is impaired in kidney patients, 76 77 leading to hyperparathyroidism and vascular calcification [8].

Hyperparathyroidism is one of the aggravating causes of anemia in hemodialysis patients, in addition to resistance to erythropoietin treatment. Defects in calcitriol synthesis, which along with parathyroid hormone stimulates calcium reabsorption, causes hypocalcemia and hyperphosphatemia in dialysis patients. In this condition, there is an increase in parathyroid

hormone synthesis to regulate calcium and phosphorus homeostasis, leading to secondary
hyperparathyroidism [9-11].

84 Abnormal levels of parathyroid hormone are associated with disorders of the musculoskeletal system and decreased function, which can lead to increased mortality in these patients. Synthesis 85 and the use of muscular energy are affected by elevated levels of this hormone, which in turn, 86 87 causes interference in amino acids and protein metabolism in the musculoskeletal system. [12,13]. In CKD patients, especially in chronic (dialysis) patients, the respiratory system is also affected 88 because both uremia and high levels of parathyroid hormone endanger lung function [14]. 89 Therefore, dialysis patients have respiratory disorders and decreased aerobic capacity due to 90 vitamin D deficiency [15] and high levels of parathyroid hormone [14]. Indeed, the functional 91 92 capacity in dialysis patients has been shown to be about 50% of what it is in healthy populations 93 [16].

The regulation of parathyroid hormone is critical for bone metabolism in healthy individuals as well as dialysis patients [17], and may be influenced by physical activity [18]. Indeed, numerous studies in healthy individuals indicate that exercise plays an important role in the regulation of this hormone [17,19-22]. However, little is known about the role of exercise especially concurrent exercise on parathyroid hormone and calcium and phosphorus metabolism in dialysis patients.

100

101 Methods

102 Trial design

This study is an open-label, parallel arm, randomized controlled trial with blinded end-points,which was conducted in a medical center in Iran.

105

106 Participants

107	Individuals were eligible to participate in the study after meeting all of the following inclusion
108	criteria: 1) age \geq 18 years; 2) receiving regular HD 3 times a week; 3) on HD for at least 1 year,
109	4) absence of a history of myocardial infarction within the past 3 months; 5) permission from
110	their physician to participate; and, 6) had capacity to provide informed consent to participate in
111	the study. Individuals were excluded if they met any of the following exclusion criteria: 1)
112	cardiac instability (angina, decompensated congestive heart failure, severe arteriovenous
113	stenosis, uncontrolled arrhythmias, etc.); 2) active infection or acute medical illness; 3)
114	hemodynamic instability (systolic blood pressure < 90 mmHg or mean arterial pressure < 60
115	mmHg); 4) labile glycemic control (extreme swings in blood glucose levels, causing
116	hyperglycemia or hypoglycemia); 5) inability to exercise (e.g. lower extremity amputation with
117	no prosthesis); 6) severe musculoskeletal pain at rest or with minimal activity; 7) inability to sit,
118	stand or walk unassisted (walking device such as cane or walker allowed); or, 8) shortness of
119	breath at rest or with activities of daily living (NYHA Class IV).
120	

121 Trial Procedures

Before starting the study, some educational and motivational posters were installed in the dialysis center, so that all patients became familiar with the benefits of exercise and especially intradialytic exercise. Then principal investigator described the side-effects of inactivity and sedentary lifestyle to all patients. Specifically, the PI encouraged all patients to be active and

126	provided information regarding potential benefits of intradialytic exercise. After providing
127	written informed consent, eligible patients received a baseline assessment. Data were collected
128	on demographic characteristics (age, sex, and time on hemodialysis), primary cause of kidney
129	failure, and comorbidities (atherosclerotic heart disease, congestive heart failure, cerebrovascular
130	accident/transient ischemic attack, peripheral vascular disease, dysrhythmia, and other cardiac
131	diseases, chronic obstructive pulmonary disease, gastrointestinal bleeding, liver disease, cancer,
132	and diabetes). Comorbidities were quantified using Charlson comorbidity index (CCI)
133	established for dialysis patients, which included the underlying cause of kidney failure, as well as
134	11 comorbidities [14].
135	Participants were then randomized in a 1:1 ratio to either the intervention group or control group.
136	The randomization sequence was generated by a study biostatistician who was not otherwise
137	involved in the study using a computer-generated random schedule (using Stata 16, Stata Crop,
138	College Station, Tx). Allocation concealment was safeguarded through the use of sequentially
139	numbered, sealed, opaque envelopes by a specified staff member who was not involved in the
140	study.
141	
142	Intervention

Subjects in the intervention group performed concurrent intradialytic exercise during the 2nd hour of dialysis (60-minute exercise sessions three times a week) for 6 months. The intervention was a combination of aerobic and resistance exercises. Workout time at the beginning was 30 minutes and gradually increased to 60 minutes. Each workout session included 5 minutes of warm-up, aerobic exercises, resistance exercises and finally 10 minutes of stretching exercises to cool down. The fistula arm was kept stationary thoroughly the exercise session, with necessary precautions taken into consideration. Also, the exercise protocol was not performed on the arm with AV fistula.

Exercises were individualized in a way that matched the level of physical fitness of participants 150 (See Additional File 1). Aerobic exercises consisted of continuously performed specified 151 152 movements, such as moving legs back and forth, shoulder abduction and adduction (hand without fistula), flexing and extending the knee, internally and externally rotating the leg, and 153 abducting and adducting the leg, in time with a played beat. 154 155 The rhythm of continuous movements was adjusted by the beats per minute of the music. This 156 meant that participants had to coordinate the movements of their arms and legs with the beats per minute of the song being played to them. In this way, the speed and intensity of aerobic exercise 157 was controlled by the rhythm. Resistance training was performed in a semi-recumbent position 158 and included exercises for the upper and lower limbs as well as core strength exercises using 159 160 body weight, weight cuffs, dumbbells, and elastic bands of varying intensity. Chest press, 161 shoulder press, triceps extension, straight arm shoulder flexion, shoulder horizontal abduction, seated row, supine grip, prone grip, neutral grip, bicep curl, leg abduction, plantarflexion, 162 163 dorsiflexion, straight-leg/bent knee raises, knee extension, and knee flexion were all part of the resistance training program. 164 All of the exercises were prescribed by an exercise physiologist who also monitored the exercise 165 166 sessions and helped patients with any questions they had. At the end of each session, the exercise 167 physiologist reviewed the adherence checklists. If a person did not attend an exercise session, a counseling session was held in the presence of a nephrologist and the exercise physiologist. The 168 reason for the individual's non-participation was investigated and the positive effects of exercise 169 170 was explained through motivational statements. When possible, patients were reminded of 171 previous benefits of exercise they had experienced as an incentive for them to increase adherence

172 with the training.

1	7	3
_	•	-

174	Participants in the control group did not undertake any specific physical activity during dialysis.
175	All other pharmacological, dialysis, dietary and management protocols were identical for
176	participants in both groups. Despite differences in some hematological parameters at baseline,
177	different medications were not used for intervention group. All participants received normal
178	bicarbonate hemodialysis, which was carried out three times a week for an average of 4 hours.
179	Volumetric ultrafiltration control was available on all machines. The standard dialysate flow rate
180	was 500 mL/min and blood flow rates were prescribed according to the participant's needs.
181	Automated methods were applied to perform dialyzer reuse uniformly.
182	
183	Blood sampling
184	Baseline blood samples were collected one day before the start of the exercise session. Exercise
185	began at the mid-week dialysis session. After the end of the 36th session (end of the third month)
186	and after the end of the 72nd session (end of the sixth month), subsequent blood samples were
187	collected the day before the midweek dialysis session. The control group was assessed at the
188	same time points. On a nondialysis day, blood samples were taken from the arterial needle after
189	at least an 8-hour fast. Approximately 30 milliliters of blood were collected and centrifuged for
190	15 minutes at 20 $^{\circ}$ C and 2500 g. Plasma was next pipetted into cryotubes and stored at -80 $^{\circ}$ C in
191	a freezer that was electronically monitored. All samples were measured in duplicate, in line with
192	the manufacturers' suggested protocol, and within the manufacturer's specified range of
193	acceptable variation and sensitivity.
194	

195 Outcomes

- 196 The primary outcome measures included changes in serum calcium (mg/dL), serum phosphorous
- 197 (mEq/L) and parathyroid hormone (pg/mL) over time. Rate of changes of alkaline phosphatase
- 198 (U/L) and calcium-phosphorous product (mg^2/dL^2) were the secondaries. These outcomes were
- evaluated at baseline, 3 months and 6 months.
- 200 Safety outcomes included all serious adverse events and adverse events.

201 Adherence

- 202 Intervention adherence was defined as the number of sessions performed divided by the number
- 203 of sessions offered, multiplied by 100.

204

205 Blinding

- 206 Due to the nature of the intervention, it was not feasible to blind participants or study staff.
- 207 However, outcome assessors and data analysts were blinded to participants' treatment
- allocations.

209 Sample size

- The sample size was calculated in accordance with a previous study [23], by NCSS PASS 16.0
- software. The model was established according to the Repeated Measure ANOVA (bilateral
- side) for the PTH as main variable, with α =0.05 and power 1 β = 0.8.
- Assuming an effect size of 0.45 for reduction of PTH and a drop-out rate of 20%, 44 participants
- 214 (22 per group) were required to provide 80% power.

215 **Statistical analysis**

- 216 Data are presented as frequency (percentage), mean \pm standard deviation, or median and
- 217 interquartile range, depending on data type and distribution. A detailed statistical analysis plan
- 218 was prepared and completed prior to database lock. Primary and secondary outcomes were

- 219 evaluated using Repeated Measure ANOVA and the Friedman test. Statistical analyses were
- performed using IBM SPSS software 25. P values less than 0.05 were considered statistically
- 221 significant.
- 222 **Results**
- 223 Overall, 58 patients were assessed for eligibility, of whom 44 were consented and randomized.
- 224 The corresponding flowchart is presented in Figure 1.




Figure 1. Participant flow during the study.

225

- 227 During the 6-month intervention period, 2 participants in the intervention group and 3
- 228 participants in the control group dropped out of the study.

229

230 **Baseline characteristics**

Baseline characteristics were balanced between the assigned treatment groups (Table 1).

Intervention (n=22)	Usual Care (n=22)
13 (59%)	15 (68%)
61 ± 14	63 ± 11
29 ± 10	25 ± 9
5 (23%)	3 (14%)
8 (36%)	9 (41%)
6 (27%)	8 (36%)
3 (14%)	3 (9%)
6.5 ± 2.3	7 ± 2
	13 (59%) 61 ± 14 29 ± 10 5 (23%) 8 (36%) 6 (27%) 3 (14%)

 Table1. Baseline characteristics of patients

Values are as mean (standard deviation) or n (%)

CCI Charlson Comorbidity Index

232 The adherence rate was $78.5\% \pm 5\%$.

233 Outcome analysis

- 234 Significant between-group changes during the 6-month intervention period were observed in all
- primary and secondary outcomes (Table 3) between the intervention and control groups.
- 236 Specifically, serum calcium tended to increase in the intervention group, but remained relatively
- stable in the control group. In contrast, serum parathyroid hormone, phosphorus, calcium-

- 238 phosphorous product and alkaline phosphatase levels significantly decreased in the intervention
- group but remained relatively stable in the control group (Table 3).
- 240 Safety
- 241 No treatment-related serious adverse effects were observed during the period of the study.
- 242 During the intervention period, one patient had muscle cramps after the first exercise session, but
- this was not serious or harmful.

Table 3. Change of primary and second	ondary outcomes and the results	of longitudinal analysis
---------------------------------------	---------------------------------	--------------------------

		Intervention			Usual care			Group
	Baseline (n=22)	3 months (n=22)	6 months (n=20)	Baseline (n=22)	3 months (n=21)	6 months (n=19)	Partial Eta Square	×Time
Ca (mg/dl)	8.1 ± 0.8	8.7 ± 0.6	9.2 ± 0.6	8.4 ± 0.7	8.6 ± 0.7	8.5 ± 0.6	0.5	<0.001**
P (meq/lit)	5.8 ± 1.4	5.1 ± 1.1	4.1 ± 0.5	5.4 ± 1.3	5.9 ± 1.2	5.3 ± 0.9	0.4	0.002**
PTH (pg/ml)	441 (364 - 597)	290 (224 - 391)	245 † (173 - 286)	270 (180 - 418)	342 (245 - 476)	312 (243 - 407)	0.8	NA
$Ca imes P (mg^2/dL^2)$	45.5 ± 4.6	43 ± 5.1	35.9 ± 4.1	43.8 ± 5.5	50.5 ± 4.9	44.2 ± 5	0.5	0.04*
ALP (U/L)	195.5 ± 8.6	148 ± 5.5	125.4 ± 7.9	203.5 ± 7.8	221.1 ± 8.3	211 ± 10.5	0.9	<0.001**

Ca serum calcium, P serum phosphorous, PTH parathyroid hormone, ALP alkaline phosphatase

Values are as mean ± standard deviation or median (interquartile)

Group ×Time is an interaction from a two-way repeated-measures analysis of the effect of time from baseline to 6 months

*p < 0.05 significant

**p < 0.01 highly significant

p < 0.01 highly significant within-group difference, analyzed by Friedman test

244

245

246 **Discussion**

Renal hyperparathyroidism is a common complication of chronic kidney disease characterized
by elevated PTH levels secondary to derangements in the homeostasis of calcium, phosphate,
and vitamin D [24].

250 Abnormalities in calcium, phosphorous, and PTH, hallmarks of the condition known as chronic 251 kidney disease – mineral and bone disorder (CKD-MBD) [25], are associated with adverse outcomes in patients receiving maintenance dialysis [7,8,26]. In patients with advanced chronic 252 253 kidney disease results in derangements of circulating markers of mineral metabolism and in dysregulation of skeletal and cardiovascular physiology [27-29]. Epidemiologic studies of 254 255 dialysis patients provide substantial evidence that elevated PTH is associated with mortality 256 [8,26]. However, therapies targeting abnormal CKD-MBD parameters, while improving 257 biochemical end points [30], have failed to convincingly demonstrate reductions in "hard" end 258 points such as all-cause and cardiovascular mortality in clinical trials [31]. The Kidney Disease 259 Improving Global Outcomes guidelines recommend that screening and management of 260 hyperparathyroidism be initiated for all patients with chronic kidney disease [25]. 261 The present study demonstrated that the 6-month intradialytic concurrent exercise program was effective in improving PTH levels, reducing serum phosphorous and improving serum calcium 262 263 and calcium-phosphorous product as well. However, contradictory results have been reported by some other studies. 264

265 Previous work showed that exercise decreased plasma PTH levels in CKD patients [32].

266 Research on effect of exercise on PTH is limited, but it is affected by physical activity. Its levels

267	can vary after physical exercise depending on the duration and intensity of the activity [33].
268	Moreover, resistance to PTH action can occur with progression of renal disease [34].
269	In the present study, phosphorus levels in the intervention group were significantly lower than
270	the baseline. The effect of exercise on phosphorus level was in line with findings of the several
271	previous studies [35,36]. Borzou et al. also reported that increasing the blood flow to 250
272	mL/min and then to 300 mL/ min can be effective in clearance of phosphorus from the blood
273	[36].

Reviewing the limited available research on the effects of exercise in reducing phosphorus levels
showed that although exercise decreased the level of phosphorus, the significant effects and
changes could be observed in long-term and perhaps more intense exercise might be required for
some studies [35,37,38].

This study revealed that serum calcium levels showed significant change in the intervention
group but Saralhab et al. like some other researchers failed to retrieve any influence of exercise
on serum calcium [24,34,39]. Perhaps studies with longer time frame and differences in type and
frequency of exercise are needed.

Cardoso et al. in their systemic review found evidence supporting a positive relation between physical activity and bone outcomes in patients with CKD [40]. Studies show that exercise acts as a regulator of homeostasis, alters the levels of circulatory mediators and hormones, and increases the demand for skeletal muscle and other vital organs for energy substrates. Exercise also activates bone and mineral metabolism, especially calcium and phosphate, both of which are essential for muscle contraction, neuromuscular signaling, adenosine triphosphate biosynthesis, and other energy substrates. Due to the fact that PHT is involved in the regulation of calcium and

phosphate homeostasis, chronic exercise may help in limiting PTH secretion exercise activity by
changing the level of calcium and phosphate in the bloodstream. On the other hand, PTH reacts
directly to exercise and exercise myokines. [33].

- Alkaline phosphatase is an enzyme measurable in most body fluids and usually originates from
- the liver or bone. In CKD patients without liver disease, ALP is a surrogate of high turnover
- bone disease and is used to monitor the metabolic bone disease associated with renal
- insufficiency [41-43]. Furthermore, elevated ALP may be causally involved in the cardiovascular
- 296 calcification of CKD [44-46], making it a potentially important independent risk factor. Higher
- ALP has been shown to be associated with mortality and coronary artery calcification in CKD
- 5D [43] and in patients without CKD [47]. In CKD, ALP is more reliable than many other
- biochemical bone markers because serum concentrations of ALP are not influenced by the
- 300 glomerular filtration rate [47]. An association exists between higher serum ALP and worse dual-
- 301 energy X-ray absorptiometry-assessed BMD in HD patients [48].
- 302 ALP levels significantly decreased in exercise group, but controls showed no similar change.
- 303 Previous observational studies on dialysis patients revealed a relationship between physical
- activity serum levels of ALP due to the fact that energy expenditure has a strong relationship tothe total BMD [49,50].
- The study by Gomes et al. and the other one by Elshinnawy et al. showed there was significant increase in ALP levels following exercise in patients with CKD [24,51].
- 308 One of the reasons for the contradiction in the process of ALP changes with the previous studies
- is that in those studies, the ALP level of the patients was within the normal range before the
- 310 intervention, and the intervention has somehow improved the condition. However, in the current

311 study, the ALP level of the patients was much higher than normal, and exercise has been able to have a significant positive effect on improving the patients' condition by reducing the ALP level. 312 313 As levels of bone specific ALP increase during weight-bearing exercise [52], but return to baseline within 20-minutes following exercise, lower resting levels may be a consequence of the 314 transient response to weight bearing exercises [53]. 315 316 Based on Mechanostat theory which was developed by Harold frost, the local deformation from 317 the mechanical loading stimulates bone cells and results in bone adaptation (it means that bone 318 tissues accommodate to the stress applied on it) [54, 55]. Without any doubt bones are subjected to two sources of load including ground reaction force and muscular force [54]. 319 High proinflammatory cytokine levels may contribute to bone loss and fracture in patients with 320 321 CKD [51]. In addition, inflammatory cytokines are potent activators of receptor activator of nuclear factor kappa B ligand / receptor activator of nuclear factor kappa B (RANKL/RANK)-322 323 activated osteoclast genesis [55]. Exercise may inactivate the RANKL/RANK pathway by 324 ameliorating inflammation and preventing bone loss in HD patients. 325 A major strength of the present study was the fact that all exercises were tailored according to 326 each individual's functional status within a pre-specified structure. There was also a high participation rate, such that included HD patients exhibited considerable diversity with respect to 327 328 demographic characteristics and associated comorbidities. In this study also, is that, at the end of 329 the study, the level of calcium, phosphorus and parathyroid hormone in the intervention group 330 reached the level recommended by KDOQI guidelines [25]. 331 This discrepancy between the results of the present study and the findings of the above-

mentioned studies can be attributed to differences in participants' age and sex or duration,

intensity, and type of exercise program. The length of the other studies is shorter. Moreover, the
 intradialytic intervention was performed as concurrent exercise which was different from other
 studies, performing only resistance or aerobic exercise.

Balanced against these strengths, the study also had a number of limitations. Not measuring the effect of exercise on bone mass and cardiovascular indexes are limitations of this study. Indeed, not measuring bone mineral density in this work is a limitation as bone strength depends on bone quality and quantity. Future work should focus on observing the effect of different types of exercise on bone mineral disorders and all-cause mortality in HD patients.

341 Conclusion

Intradialytic exercise performed for at least 60 minutes during thrice weekly dialysis sessions improves bone mineral metabolism in adult patients receiving HD and perhaps decrease all-cause mortality in these patients. Further studies should focus on observing the effect of different types of exercise on bone mineral disorders and all-cause mortality in HD patients.

346 **Declaration**

347 Ethics approval and consent to participate

348 The study protocol and informed consent were approved by Iran National Committee for Ethics

- in Biomedical Research (approval number IR.IAU.KHUISF.REC.1400.088) and was conducted
- in accordance with principles of the Declaration of Helsinki. All patients provided written
- 351 informed consent prior to enrollment.

352 **Consent for publication**

353 Not applicable

354 **Competing interest**

355 The authors declare that they have no competing interest.

356 Funding

357 Not applicable

358 Authors' Contribution

359 MAT: conceptualizing the study, project leader of the study, conducting the study, writing of the manuscript, supervising of the analysis, interpreting the results, approval of the manuscript, KW: 360 conceptualizing of the study, co-writing of the manuscript, supervising of the manuscript, 361 approval of the manuscript, NS: project leader of the study, analyzing the data, interpreting the 362 363 results, co-writing of the manuscript, approval of the manuscript, SN: conceptualizing the study, 364 conducting the study, co-writing of the manuscript, supervising of the manuscript, approval of 365 the manuscript, MS: conceptualizing the study, conducting the study, co-writing of the 366 manuscript, supervising of the manuscript, approval of the manuscript, ZR: conceptualizing the 367 study, conducting the study, co-writing of the manuscript, supervising of the manuscript, approval of the manuscript, SA: conceptualizing the study, conducting the study, co-writing of 368 369 the manuscript, approval of the manuscript. Each author contributed with important intellectual content during the manuscript drafting or revision and accepts accountability for the overall work 370 371 by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are 372 appropriately investigated and resolved. All authors read and approved the final manuscript.

373

374 Acknowledgement

375	The authors would like to express their heart-felt gratitude to all the investigators for their
376	contribution to the trial, especially Dr. Hugo Corrêa1 and Dr. João and all the staff of the dialysis
377	center for their efforts and patience in helping to maintain the standards of the research, as well
378	as all patients involved in this study. Also, the authors would like to thank Pardis Specialized
379	Wellness Institute and all the personnel of the institute for their support throughout the study.
380	The authors would also like to thank the opportunity that medRxiv offered them to deposit the
381	preprint version.
382	
383	
384	
385	References
386	1. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, et al. Epidemiology,
387	contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet.
388	2014;383(9931):1831–43
389	2. United States Renal Data System. Epidemiology of kidney disease in the United States.
390	National Institutes of Health, National Institute of Diabetes and Digestive and Kidney
391	Diseases, Bethesda, MD, 2018. Available at
392	https://www.usrds.org/2018/view/Default.aspx.
393	3. Deligiannis A, D'Alessandro C, Cupisti A. Exercise training in dialysis patients: impact
394	on cardiovascular and skeletal muscle health. Clin Kidney J. 2021 Jan 11;14(Suppl
395	2):ii25-ii33. doi: 10.1093/ckj/sfaa273. PMID: 33981417; PMCID: PMC8101623.

396	4.	SONG Initiative. The SONG Handbook. Version 1.0 June 2017, Sydney, Australia
397		Available at songinitiative.org/reports-and-publications/.
398	5.	Manera KE, Tong A, Craig JC, Shen J, Jesudason S, Cho Y, et al. An international
399		Delphi survey helped develop consensus-based core outcome domains for trials in
400		peritoneal dialysis. Kidney Int. 2019;96(3):699–710.
401	6.	D. S. March, M. P. M. Graham-Brown, C. M. Stover, N. C. Bishop, and J. O. Burton,
402		"Intestinal Barrier sturbances in Haemodialysis Patients: Mechanisms, Consequences,
403		and Therapeutic Options," BioMed Research International, vol. 2017, Article ID
404		5765417, 2017.
405	7.	Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and
406		calcium phosphate product with mortality risk inchronic hemodialysis patients: a national
407		study. Am J Kidney Dis 1998; 31: 607–617.
408	8.	Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity
409		in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208–2218.
410	9.	Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca PO(4)
411		product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis
412		patients. J Am Soc Nephrol 2001; 12: 2131–213
413	10	. Stevens LADO, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid
414		hormone levels in combination and as a function of dialysis duration predict mortality:
415		evidence for the complexity of the association between mineral metabolism and utcomes.
416		J Am Soc Nephrol 2004; 15: 770.

417	11. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and
418	cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J
419	Am Soc Nephrol 2005; 16: 1788–1793.
420	12. Albuquerque RFC, Carbonara CEM, Martin RCT, Reis LM, Nascimento Jr CP, Arap SS,
421	et al. Parathyroidectomy in patients with chronic kidney disease: Impacts of different
422	techniques on the biochemical and clinical evolution of secondary hyperparathyroidism.
423	Surgery. 2018;163(2):381-7
424	13. Campos SR, Gusmão MHL, Fortes A, Sampaio LR, Barreto JM. Estado nutricional e
425	ingestão Estado nutricional e ingestão alimentar de pacientes em diálise peritoneal
426	contínua com e sem hiperparatireoidismo secundário. J Bras Nefrol. 2012;34(2):170-7
427	14. Coelho DM, Castro ADM, Tavares HA, Abreu PBC, Glória RR, Duarte MH, et al.
428	Efeitos de um Programa de Exercícios Físicos no Condicionamento de Pacientes em
429	Hemodiálise. J Bras Nefrol. 2006;28(3):121-7.
430	15. Duarte J, Medeiros RF, Di Pietro T, Lopes TM. Alterações de volumes e capacidades
431	pulmonares pré e pós-hemodiálise em insuficiência renal crônica TT Changes in lung
432	volume and capacity before and after hemodialysis in chronic renal failure. J Heal Sci
433	Inst. 2011;29(1):70-2
434	16. Fassbinder TRC, Winkelmann ER, Schneider J, Wendland J, Oliveira OB. Functional
435	Capacity and Quality of Life in Patients with Chronic Kidney Disease In Pre-Dialytic
436	Treatment and on Hemodialysis - A Cross sectional study. J Bras Nefrol. 2015;37(1):47-
437	54

- 438 17. Maïmoun, L., Lumbroso, S., Manetta, J., Paris, F., Leroux, J.L. and Sultan, C. (2003)
- 439 Testosterone is significantly reduced in endurance athletes without impact on bone
- 440 mineral density. Hormone Research 59, 285–292
- 18. Glastre, C., Braillon, P., David, L., Cochat, P., Meunier, P.J. and Delmas P.D. (1990)
- 442 Measurement of bone mineral content of the lumbar spine by dual energy x-ray
- 443 absorptiometry in normal children: correlations with growth parameters. The Journal of
- 444 Clinical Endocrinology and Metabolism 70, 1330-1333.
- 19. Thorsen, K., Kristoffersson, A., Hultdin, J. and Lorentzon, R. (1997) Effects of moderate
- endurance exercise on calcium, parathyroid hormone, and markers of bone metabolism in
- 447 young women. Calcified Tissue International 60, 16-20.
- 20. Brahm, H., Piehl-Aulin, K. and Ljunghall, S. (1997a) Bone metabolism during exercise
 and recovery: the influence of plasma volume and physical fitness. Calcified Tissue
 International 61, 192-198.
- 451 21. Ljunghall, S., Joborn, H., Roxin, L.E., Skarfors, E.T., Wide, L.E. and Lithell, H.O.
- 452 (1988) Increase in serum parathyroid hormone levels after prolonged physical exercise.
- 453 Medicine and Science in Sports Exercise 20, 122-125
- 454 22. Zerath, E., Holy, X., Douce, P., Guezennec, C.Y. and Chatard, J.C. (1997) Effect of
- 455 endurance training on postexercise parathyroid hormone levels in elderly men. Medicine456 and Science in Sports and Exercise 29, 1139-4115.
- 457 23. Elshinnawy, H.A., Mohamed, A.M.B.B., Farrag, D.A.B. et al. Effect of intradialytic
- 458 exercise on bone profile in hemodialysis patients. Egypt Rheumatol Rehabil 48, 24
- 459 (2021).

460	24. Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of Renal Disease.
461	Perm J. 2016 Summer;20(3):15-127. doi: 10.7812/TPP/15-127. Epub 2016 Jul 22.
462	25. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2017)
463	KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention,
464	and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney
465	Int Suppl 7:1–59. 2009;76(Suppl 113):S1-S130.
466	26. Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and
467	association with outcomes among patients with secondary hyperparathyroidism on
468	chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98–109.
469	27. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a
470	growing concern. Kidney Int. 2008;74(6):721-731.

- 471 28. Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. Cardiovascular risk in chronic
- 472 kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD) Pediatr Nephrol.
 473 2010;25(4):769–778.
- 474 29. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin
 475 Invest. 2011;121(11):4393–4408.
- 30. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism
 and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67(2):760–771.
- 478 31. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular
 479 disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–2494.
- 480 32. Bouassida A, Latiri I, Bouassida S, Zalleg D, Zaouali M, Feki Y, Gharbi N, Zbidi A,
- 481 Tabka Z (2006) Parathyroid hormone and physical exercise: a brief review. J Sports Sci
- 482 Med 5(3):367–374

483	33. Lombardi G, Ziemann E, Banfi G, Corbetta S (2020) Physical activity- dependent
484	regulation of parathyroid hormone and calcium-phosphorous metabolism. Int J Mol Sci
485	21(15):5388.
486	34. Makhlough A, Ilali E, Mohseni R, Shahmohammadi S. Effect of intradialytic aerobic
487	exercise on serum electrolytes levels in he- modialysis patients. Iran J Kidney Dis.
488	2012;6(2):119–23.
489	35. Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG. Time and exercise improve
490	phosphate removal in hemodialysis patients. Am J Kidney Dis. 2004;43(1):85–9.
491	36. Borzou SR, Gholyaf M, Zandiha M, Amini R, Goodarzi MT, Torka- man B. The effect of
492	increasing blood flow rate on dialysis adequacy in hemodialysis patients. Saudi J Kidney
493	Dis Transpl. 2009;20(4):639–42.
494	37. Asadi Noghabi A, Bassampour SH, Zolfaghari M. Critical care nursing ICU, CCU,
495	dialysis. Salemi publication; 2th ed. 2007; p. 448-53.
496	38. Cappy CS, Jablonka J, Schroeder ET. The effects of exercise during hemodialysis on
497	physical performance and nutrition assessment. J Ren Nutr. 1999;9:63-70.
498	39. Salhab N, Alrukhaimi M, Kooman J, Fiaccadori E, Aljubori H, Rizk R, Karavetian M
499	(2019) Effect of intradialytic exercise on hyperphosphatemia and malnutrition. Nutrients
500	11(10):2464.
501	40. Cardoso, D.F., Marques, E.A., Leal, D.V. et al. Impact of physical activity and exercise
502	on bone health in patients with chronic kidney disease: a systematic review of
503	observational and experimental studies. BMC Nephrol 21, 334 (2020).

41. Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MW, Larsson L: Effect of
chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney
Int 60: 257–265, 2001
42. Torres PU. Bone alkaline phosphatase isoforms in chronic renal failure. Kidney Int.
2002;61:1178–1179.
43. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts
mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19:2193-
2203.
44. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC. Upregulation of alkaline
phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular
calcification. Kidney Int. 2008;73:1024–1030.
45. O'Neill WC. Pyrophosphate, alkaline phosphatase, and vascular calcification. Circ Res.
2006;99:e2.
46. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular
calcification in renal failure? . Kidney Int. 2008;73:989–991.
47. Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum
phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120:1784–1792.
48. Park JC, Kovesdy CP, Duong U, Streja E, Rambod M, Nissenson AR, Sprague SM,
Kalantar-Zadeh K. Association of serum alkaline phosphatase and bone mineral density
in maintenance hemodialysis patients. Hemodial Int. 2010 Apr;14(2):182-92. doi:
10.1111/j.1542-4758.2009.00430.x. Epub 2010 Mar 24.

525	49. Huang G-S, Chu T-S, Lou M-F, Hwang S-L, Yang R-S. Factors associated with low bone
526	mass in the hemodialysis patients - a cross-sectional correlation study. BMC
527	Musculoskelet Disord. 2009;10:60.
528	50. Ota S, Takahashi K, Taniai K, Makino H. Bone metabolism and daily physical activity in
529	women undergoing hemodialysis. Nihon Jinzo Gakkai Shi. 1997;39(4):441-6.
530	51. Gomes TS, Aioke DT, Baria FG, Graciolli FG, Moyses RMA, Cuppari L (2017) Effect of
531	aerobic exercise on markers of bone metabolism of overweight and obese patients with
532	chronic kidney disease. J Ren Nutr 27(5):364–371.
533	52. Rudberg A, Magnusson P, Larsson L, Joborn H. Serum isoforms of bone alkaline
534	phosphatase increase during physical exercise in women. Calcif Tissue Int. 2000;66:
535	342–347. pmid:10773103
536	53. Fragala MS, Bi C, Chaump M, Kaufman HW, Kroll MH (2017) Associations of aerobic
537	and strength exercise with clinical laboratory test values. PLOS ONE 12(10): e0180840.
538	54. Frost HM. The mechanostat: a proposed pathogenic mechanism of osteoporoses and the
539	bone mass effects of mechanical and nonmechanical agents. Bone Miner. 1987;2(2):73-
540	85.
541	55. Frost HM. Bone's mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol.
542	2003;275(2):1081–1101.
543	56. Liao M-T, Liu W-C, Lin F-H, Huang C-F, Chen S-Y, Liu C-C, et al. Intradialytic aerobic
544	cycling exercise alleviates inflammation and improves endothelial progenitor cell count
545	and bone density in hemodialysis patients. Medicine.2016;95(27):e4134.